FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new hybrid immunoglobulins; it can be used in medicine. The invention discloses polypeptides capable of binding to proteoglycan cartilage aggrecan protein. ADAMTS5, and/or MMP13, as well as structures based on them.
EFFECT: invention can be used in medical practice in the treatment or prevention of joint diseases for prevention of cartilage tissue erosion, in particular in osteoarthritis.
21 cl, 11 dwg, 25 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
MMP13-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2784069C2 |
ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND THEIR USE | 2015 |
|
RU2807602C2 |
IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
Authors
Dates
2022-12-23—Published
2018-06-04—Filed